Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: BNT116
BIOLOGICAL: Cemiplimab
DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Paclitaxel
BIOLOGICAL: BNT316
BIOLOGICAL: anti-B7-H3 antibody conjugated to topoisomerase I inhibitor
BIOLOGICAL: anti-HER3 antibody conjugated to topoisomerase I inhibitor
BIOLOGICAL: Bispecific antibody for PD-L1 and VEGF-A
BIOLOGICAL: Osimertinib
BIOLOGICAL: ALK-inhibitor or RET-inhibitor

Sponsor

BioNTech SE